Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: A report from the intergroup rhabdomyosarcoma study group
Philip P. Breitfeld, Elizabeth Lyden, R. Beverly Raney, Lisa A. Teot, Moody Wharam, Thom Lobe, William M. Crist, Harold M. Maurer, Sarah S. Donaldson, Frederick B. Ruymann, James R. Anderson, Richard J. Andrassy, Carola A.S. Arndt, K. Scott Baker, Frederic G. Barr, W. Archie Bleyer, Philip Breitfeld, John C. Breneman, Julia Bridge, Kenneth BrownHolcombe E. Grier, Douglas Hawkins, Peter J. Houghton, Michael Link, William H. Meyer, Jeff Michalski, Sharon Murphy, Charles N. Paidas, Alberto S. Pappo, David M. Parham, Stephen J. Qualman, Leslie Robison, Eric Sandler, Lynn Smith, Poul H.B. Sorensen, Lisa Teot, Timothy Triche, Teresa J. Vietti, David Walterhouse, Eugene S. Wiener, Suzanne Wolden, Richard Womer, Joan L. Leeson
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: A report from the intergroup rhabdomyosarcoma study group'. Together they form a unique fingerprint.